Skip to main content
OpenTrials
Completed

NCT Number: NCT05439551

Evaluating the Analytical Equivalency of Serum and Whole Blood Samples Run on the MeMed Key® Platform (Perseverance Study)

This is a Prospective, multi-center, sample collection study enrolling pediatric and adult subjects presented to the ED/Urgent care, with symptoms consistent with acute bacterial or viral infection will be recruited according to eligibility criteria. The study is designed to measure the MeMed BV®️ score in whole blood and serum samples and demonstrate the equivalence between the two matrices. Patients will be managed according to the current standard of care per standard institutional procedures.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

90 day and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hillel Yaffe Medical Center, Hadera, Israel

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent must be obtained from the patient or his/her legal guardian. For children under 18 years old, written informed consent from the legal guardian must be obtained and assent from the patient may be required depending on the local requirements.
  • Over 90 days of age.
  • Clinical suspicion of acute bacterial or viral infection.
  • Symptoms of acute infectious disease < 7 days.
  • Experienced fever at least once within the last 7 days (self-reported or Temperature ≥ 37.8°C (100°F)).

Exclusion criteria

  • HIV, HBV, active HCV, or active Tuberculosis infection (self-declared or known from medical records).
  • Suspicion and/or confirmed diagnosis of infectious gastroenteritis/ colitis.
  • Active inflammatory disease (e.g., IBD, SLE, JIA, RA, Kawasaki, other vasculitis).
  • Pregnancy- self reported or medically confirmed.
  • Active malignancy.
  • Congenital or acquired immune deficiency (CID).
  • A proven or suspected infection on presentation with Mycobacterial (e.g., Tuberculosis, MAC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen.
  • Significant trauma or burns in the last 7 days.
  • Patients that have undergone major surgery in the last 7 days.
  • Current treatment with immune-suppressive or immune-modulating therapies, including without limitations:
  • Administration of P.O.\\IV\\IM high dose steroids >1mg/kg/day prednisone (or equivalent) at some point in the past 10 days or daily continuous use of steroids > 0.25 mg/kg/day in the past 7 days
  • Monoclonal antibodies, anti-TNF agents
  • Intravenous immunoglobulin (IVIG)
  • Cyclosporine, Cyclophosphamide, Tacrolimus, Azathioprine, Methotrexate
  • G/GM-CSF, Interferons.

Treatment and study plan

MeMed BV®

Diagnostic Test

Patients Serum and Whole blood samples will be examined using the MeMed BV® test. Test results will have no impact on patient management.

Primary outcomes

  1. Measuring the MeMed BV® score with whole blood and serum samples from patients suspected of acute bacterial or viral infection and demonstrating the equivalence between the two matrices.

    Time frame: Through study completion, an average of 18 months

Sponsors and collaborators

Lead sponsor

MeMed Diagnostics Ltd.

Industry

Registry information

Official study title

A Prospective Multi-center Sample Collection Study for Evaluating the Analytical Equivalency of Serum and Whole Blood Samples Run on the MeMed Key® Platform ("Perseverance" Study)

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Jun 30, 2022
Registry last updated
Oct 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.